James J Ferguson
Affiliation: Texas Medical Center
- Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directionsJ J Ferguson
St Luke s, Episcopal Hospital, Cardiology Research, Houston, TX 77030, USA
Drugs 58:965-82. 1999..Ongoing and future studies will further refine the role of GP IIb/IIIa antagonists, explore new applications, and further test their safety and cost effectiveness in the short and long term...
- The role of oral antiplatelet agents in atherothrombotic diseaseJames J Ferguson
Texas Heart Institute, St Luke s Episcopal Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiovasc Drugs 6:149-57. 2006..Recent data suggest that clopidogrel may have a significant role, with or without fibrinolytic therapy, in the immediate management of ST-segment elevation ACS...
- Of Swiss alchemists and road hazardsJames J Ferguson
Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston, Texas Heart Institute, Houston, Texas, USA
J Invasive Cardiol 19:437-8. 2007
- Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) studyJames J Ferguson
Cardiology Research 1 191, St Luke s Episcopal Hospital, Houston, Tex 77225, USA
Am Heart J 146:628-34. 2003....
- Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMIJ J Ferguson
Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston 77030, USA
Minerva Cardioangiol 55:529-56. 2007....
- Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromesJames Ferguson
Cardiology Research, M C 1 19, St Luke s Episcopal Hospital, P O Box 20269, Houston, TX 77225, USA
J Invasive Cardiol 16:136-44. 2004..The combined use of a LMWH and a GP IIb/IIIa antagonist should now be viewed as safe and effective in the management of acute coronary syndromes. Definitive efficacy-powered superiority data will be available shortly...
- If there's smoke, is there fire?James J Ferguson
Texas Heart Institute, St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, TX 77225 0345, USA
Circulation 109:1442-4. 2004
- Low molecular weight heparins and glycoprotein IIb/IIIa antagonistsJames J Ferguson
St Luke s Episcopal Hospital, Texas Heart Institute, University of Texas Health Science Center at Houston, Baylor College of Medicine, Houston, Texas, USA
J Interv Cardiol 15:147-54. 2002..As the standard of care moves forward, we will see increasing use of LMWHs, with and without GP IIb/IIIa antagonists in conservatively and invasively managed patients...
- The current practice of intra-aortic balloon counterpulsation: results from the Benchmark RegistryJ J Ferguson
Texas Heart Institute, Houston, Texas 77030, USA
J Am Coll Cardiol 38:1456-62. 2001....
- Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on EnoxaparinJ J Ferguson
Cardiology Research, St Luke s Episcopal Hospital, Houston, TX 77225, USA
J Invasive Cardiol 12:E10-3;discussion E25-8. 2000..NICE 3 builds on the previous experiences of NICE 1 and NICE 4 with LMWH in the cath lab (with or without GP IIb/IIIa antagonists) to more aggressively extend the use of LMWHs into the medical management of ACS patients...
- Angiography and interventional cardiologyJames J Ferguson
Cardiology Research, St Luke s Episcopal Hospital, Houston, Texas 77030, USA
J Am Coll Cardiol 44:13A-15A. 2004
- Safety of enoxaparin versus unfractionated heparin during percutaneous coronary interventionJose G Diez
Department of Internal Medicine, Texas Heart Institute at St Luke s Episcopal Hospital, USA
Tex Heart Inst J 36:98-103. 2009..Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings...
- Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decadeGlenn N Levine
Baylor College of Medicine and the Houston VA Medical Center, Houston, Texas 77030, USA
Catheter Cardiovasc Interv 66:149-57. 2005..The percentages of patients undergoing invasive and revascularization procedures were consistently higher in the U.S. cohorts of study subjects when compared to non-U.S. cohorts of study subjects...
- Defining the scope of evidence-based practice for low-molecular-weight heparin therapy in high-risk patients with unstable angina and non-ST-elevation myocardial infarctionJames J Ferguson
Cardiology Research, St Luke s Episcopal Hospital, Texas Heart Institute, Houston 77030, USA
Clin Cardiol 25:I16-22. 2002..At present, however, practitioners need to consider individually how comfortable they are with the available data...
- Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendationsGlenn N Levine
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Catheter Cardiovasc Interv 60:185-93. 2003
- Low-molecular-weight heparins in the cardiac catheterization laboratoryRajan A Kadakia
Department of Cardiology Research, Texas Heart Institute, St Luke s Episcopal Hospital, Houston, Texas 77225 0269, USA
Tex Heart Inst J 31:72-83. 2004....
- Circadian body temperature variability is an indicator of poor prognosis in cardiomyopathic hamstersAmany Ahmed
Texas Heart Institute at St Luke s Episcopal Hospital, 6770Bertner Avenue, Houston, TX 77030, USA
J Card Fail 16:268-74. 2010..Our goal was to use cardiomyopathic hamsters to examine the relationship between body temperature and heart failure decompensation and death...
- Left ventricular electromechanical mapping: preliminary evidence of electromechanical changes after successful coronary interventionEmerson C Perin
Department of Adult Cardiology, Texas Heart Institute St Luke s Episcopal Hospital, and Baylor College of Medicine, Houston, Tex, USA
Am Heart J 144:693-701. 2002..Postinterventional ischemic myocardial dysfunction and its sequelae are still not well understood...
- Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicineJohn F Canales
Department of Cardiology Research, Texas Heart Institute at St Luke s Episcopal Hospital, Baylor College of Medicine, The University of Texas Health Science Center at Houston, Houston, Texas 77225 0269, USA
Am J Cardiovasc Drugs 8:15-25. 2008....
- Direct stenting and placement of a distal protection device after laser angioplasty in a saphenous vein graft with severe stenosisShun Kohsaka
Department of Cardiology, Texas Heart Institute, St Luke s Episcopal Hospital, 6720 Bertner Avenue, M C 1 133, Houston, TX, USA
J Invasive Cardiol 17:160-2. 2005
- Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularizationEric J Topol
Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Am J Med 113:1-6. 2002..Brief intervention with this monoclonal antibody during percutaneous coronary revascularization is associated with significant improvement of long-term survival...
- Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removalWarren J Cantor
Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Catheter Cardiovasc Interv 69:73-83. 2007..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, RevasHarvey D White
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
Am Heart J 152:1042-50. 2006..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
- Strategies for optimizing outcomes in the NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel ReportMarc Cohen
J Invasive Cardiol 18:617-39. 2006..The addition of statins, ACE-inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
- Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)Melvin R Echols
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 99:315-21. 2007..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
- Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trialChadwick D Miller
Department of Emergency Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
Eur Heart J 28:1079-84. 2007..We compared the initial treatment and clinical outcomes of patients presenting with evolving MI (EMI) with those presenting with MI...
- Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensusDean J Kereiakes
Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
Am Heart J 144:615-24. 2002....
- Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trialPierluigi Tricoci
Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
Circulation 116:2669-77. 2007..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
- Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--IIIMarc Cohen
Cardiac Cath Lab, 2nd Floor Bridge, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, 07112, USA
J Invasive Cardiol 19:525-38; quiz 539-40. 2007..The addition of statins, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
- Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey
Duke Clinical Research Institute, Durham, NC 27715, USA
J Gen Intern Med 23:310-6. 2008..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
- Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapyDerek P Chew
Flinders Medical Centre, South Australia, Adelaide, Australia
Am Heart J 155:239-44. 2008..We explored the clinical outcomes among high-risk patients undergoing CABG and the impact of modern pharmacology...
- Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patientsVictor L Serebruany
HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD, USA
Fundam Clin Pharmacol 22:315-21. 2008..This excess risk should be considered when choosing the optimal antiplatelet strategy for long-term treatment of patients with prior occlusive vascular events or those at high risk of developing occlusive vascular disease...
- Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndromeSteve Leung
University of Kentucky, Lexington, KY, USA
Am Heart J 156:177-84. 2008..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
- A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesMarc Cohen
HEART Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
J Am Coll Cardiol 48:1346-54. 2006....
- Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJames J Ferguson
JAMA 292:45-54. 2004..Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy...
- Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJohn L Petersen
Duke Clinical Research Institute, Durham, NC 27715, USA
JAMA 292:89-96. 2004....
- Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACSDean J Kereiakes
The Lindner Center for Research and Education, Ohio State University, Cincinnati, USA
J Invasive Cardiol 15:536-53. 2003
- Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 148:269-76. 2004..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
- Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trialKenneth W Mahaffey
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 149:S81-90. 2005..However, the critical trials comparing enoxaparin with UFH were conducted before the widespread use of early invasive management and the availability of clopidogrel and glycoprotein IIb/IIIa receptor antagonists...
- High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey
Duke Clinical Research Institute, Durham, NC 27715, USA
JAMA 294:2594-600. 2005....
- A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromesRobert M Califf
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
Am Heart J 149:S91-9. 2005..Contemporary guidelines from the American College of Cardiology/American Heart Association call for use of low-molecular-weight heparin or unfractionated heparin (UFH)...
- Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registryGregg W Stone
Cardiovascular Research Foundation and Lenox Hill Hospital, 55 East 59th Street, 6th Floor, New York, NY 10022, USA
J Am Coll Cardiol 41:1940-5. 2003..We sought to examine contemporary utilization patterns and clinical outcomes in patients with acute myocardial infarction (AMI) requiring intra-aortic balloon pump (IABP) counterpulsation...
- 2004: that was the year that wasJames J Ferguson
Tex Heart Inst J 32:2-6. 2005
- Comparison of outcomes after 8 vs. 9.5 French size intra-aortic balloon counterpulsation catheters based on 9,332 patients in the prospective Benchmark registryMarc Cohen
Division of Cardiology, M C P Hahnemann University, Philadelphia, Pennsylvania, USA
Catheter Cardiovasc Interv 56:200-6. 2002..The large, population-based, ongoing Benchmark registry provides a useful vehicle for outcomes research concerning the evolving practice of IABC...
- Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark RegistryMarc Cohen
Division of Cardiology, MCP Hahnemann University School of Medicine, PA, Philadelphia, USA
Eur Heart J 24:1763-70. 2003..To examine differences in patient characteristics and outcomes in 19636 patients enrolled in the USA and 3027 patients enrolled in other countries undergoing intra-aortic balloon pump (IABP) counterpulsation...
- Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predictDerek P Chew
Flinders Medical Centre, Adelaide, Australia
Am Heart J 155:841-7. 2008..We assessed the ability to predict need for CABG from demographics known at the time of ACS presentation, using data from SYNERGY...
- A word from the dark sideJames J Ferguson
Tex Heart Inst J 35:1. 2008
- Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Circulation 106:1243-50. 2002..No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI...
- In-hospital mortality associated with the use of intra-aortic balloon counterpulsationPhilip M Urban
La Tour Hospital, Geneva, Switzerland
Am J Cardiol 94:181-5. 2004..Therefore, diagnostic evaluation and treatment decisions should be made as early as possible, and physicians should be aware of associated risk factors in making choices for patients...
- Retroactive indexing: the apotheosis of a laboratory bulletin?James J Ferguson
Tex Heart Inst J 31:205. 2004
- The times, they ARE a changin'James J Ferguson
Tex Heart Inst J 30:95-6. 2003
- Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgeryJan T Christenson
Department of Cardiovascular Surgery, University Hospital, Geneva, Switzerland
Ann Thorac Surg 74:1086-90; discussion 1090-1. 2002..Although the efficacy and cost-effectiveness of IABC have been demonstrated, historically higher complication rates have dissuaded some practitioners from using IABC...
- Assessing risk after acute myocardial infarctionGary M Idelchik
J Am Coll Cardiol 49:2227; author reply 2227-8. 2007
- Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?Elliott M Antman
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
Circulation 108:2604-7. 2003